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Objective:Thesearchforanidealtemporaryskinsubstituteisacontinuousquest.With-
out the ability to provide active transport systems powered by adenosine triphosphate
or adenosine diphosphate that pump fluid out on demand, all skin substitutes, however
effective, would be a compromise. Therefore, the best that any current wound covering
design can do is to strive to produce all the other qualities of an ideal skin substitute.
Recently developed technology utilized in AWBAT attempts to better maximize those at-
tributes.Methods:Desirabletraitsofanidealskinsubstituteincludeadherence,moisture
permeability control, infection control, safety, pain management, physical adaptability,
transparency, stability, cost-effectiveness, and ease of application and removal. Analy-
sis of the optimization of these traits exemplifies the proficiency of a skin substitute.
Results: Improvements in porosity and manufacturing methodology intend to increase
AWBAT’s capability over existing products to better fulfill the ideal properties of a skin
substitute. Conclusion: It is expected that new technological improvements in AWBAT
willprovideimprovedperformanceoverexistingskinsubstitutes.Increasedporosityand
continuity of the 3-dimensional silicone-nylon membrane are expected to improve acute
adherence and reduce the potential for infection associated with fluid accumulation, and
theeliminationofcross-linkingagentsinthecollagenapplicationisexpectedtoimprove
theinteractionwithfibrinandeliminatethepotentialforallergicreactiontothoseagents.
The search for an ideal temporary skin substitute, or bioengineered alternative tissue,
for the effective closure of superficial, partial-thickness, and excised full-thickness wounds
is continually ongoing. At this point, the best any temporary skin replacement system can
doistomaximizetheattributesoftheidealskinsubstitute.Forexample,sincecurrentstate-
of-the-art bioengineering and biotechnology are not capable of designing active transport
systems powered by adenosine triphosphate or adenosine diphosphate into skin substitutes
to pump fluid out on demand, any skin substitute, however effective, is a compromise.
Biobrane, the first biologically based wound dressing cleared by the FDA1 in 1979, was
designed with the ideal properties in mind. Since then, many dressings have been intro-
duced, but, to date, none has provided an optimal solution. Recently, principles of biochem-
istry and bioengineering have been employed to create AWBAT, which was cleared by the
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FDA in February, 2009. AWBAT has been designed to provide the clinician with the most
advantageous temporary skin substitute.
Biobrane has been proven in multicenter trials to be an effective alternative to fresh
and frozen allograft and glutaraldehyde-treated porcine xenograft.2,3 AWBAT, an extension
of the design of Biobrane, is intended to better satisfy the desired attributes of an ideal
temporary skin substitute.4–8 Significant design changes to the silicone-nylon membrane
includeincreasedporosityofthesiliconelayerandthecontinuityofthe3-dimensionalnylon
structure. Additional changes include the elimination of the cross-linking agents, cyanuric
acid and dodecylamine, utilized in Biobrane to covalently bond the porcine type 1 collagen
peptide to the silicone-nylon membrane.9
NOMENCLATURE
Alternative terminology10 has been proposed for products referred to as “bioengineered
skin,” “bioengineered skin substitutes,” “tissue-engineered skin,” and “bioengineered skin
equivalents.” The new term, bioengineered alternative tissue, applies to products like Bio-
brane, Integra, TransCyte, Alloderm, Orcell, Oasis, Epicel, GammaGraft, and Laserskin.
Compositionoftheseproductsincludesxenogenicmaterial,suchascollagenorchondroitin
sulfate, and other biologically derived components, living cells and synthetic materials.
AWBAT (Advanced Wound Bioengineered Alternative Tissue) is a precision, porous sil-
icone membrane bonded with a continuous 3-dimensional nylon structure that contains
non–cross-linked porcine type 1 collagen peptides.
In this article, the term skin substitute is intended to mean a “bioengineered alternative
tissue” to skin for temporary coverage of donor sites, meshed autografts, partial-thickness
burns, or excised full-thickness wounds until autograft is available for permanent closure.
IDEAL PROPERTIES OF A TEMPORARY SKIN SUBSTITUTE
The desirable properties of an ideal temporary skin substitute include the maximization
of adherence, moisture permeability control, infection control, safety, pain management,
physical adaptability, transparency, stability, cost-effectiveness, and ease of application and
removal.
Adherence
Adherence is believed to be the single most important property of a skin substitute.4–6,11
Adherenceofbovinecollagenmembranecross-linkedwithglutaraldehydewasshowntobe
superiortoautograft,homograft,andxenograftonfull-thicknessandsplit-thicknesswounds
but inferior to autograft and homograft on granulating wounds.12,13 In the development of
Biobrane, adherence testing using the quantitative model of Tavis et al was performed
on various prototypes. In this study, Biobrane’s silicone-nylon membrane had a variety of
biological compounds covalently bonded to all surfaces; the composites were tested for
adherence at 5 and 72 hours. The bound elements included heparin, chondroitin-4-sulfate,
egg albumin, collagen (tropocollagen—rat skin), lysine, fibrinogen, hemoglobin, aspar-
tic acid, alanine, glutamic acid, glycine, glycylglycine, human albumin, collagen peptide
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(porcine type 1) and lecithin. The one combination that exhibited the best acute adherence
over the control, which had nothing added, was the silicone-nylon membrane with porcine
type 1 collagen peptide.9
AWBAT, like Biobrane, is a porous silicone-nylon membrane utilizing porcine type 1
collagen peptides. Adherence of AWBAT, however, is anticipated to be superior to Biobrane
for 2 reasons. First, the collagen in AWBAT is not cross-linked to the silicone-nylon
membrane as it is in Biobrane; therefore, without steric hindrance it is expected to react
more quickly with the fibrin in the wound to achieve clotting and acute adherence, within
the 3-dimensional nylon structure. Second, the porosity increase from Biobrane to AWBAT,
which is 500% to 1000% (Table 1), is expected to reduce fluid accumulation beneath the
dressing and minimize fluid pressure that might force the skin substitute from the wound
bed.
Moisture permeability control
Amoistwoundenvironment4,14 isveryimportanttomaximizewoundhealingandminimize
infection complications; however, fluid accumulation beneath a skin substitute can com-
promise adherence and provide a site for endogenous bacteria to proliferate. Therefore, it is
importantthatadressingsimultaneouslyallowmoistureretention,gaseoustransfer,andex-
udatedrainage.Thisisaccomplishedthroughaprecisionporoussiliconemembranedesign.
Gases, such as oxygen, carbon dioxide, and water vapor, diffuse through solid yet thin
silicone membranes, which have been successfully used as membrane oxygenators.15 The
thickness of the silicone membrane for successful transfer of gases, per the Lande-Edwards
Membrane Oxygenator, is 0.001 inch or less. Both Biobrane9 and AWBAT have this similar
siliconethickness,allowingforgaseoustransmissionwhilemaintainingtheabilitytocontrol
water vapor loss.
While a solid silicone membrane is necessary to control water vapor loss, in order
to minimize fluid accumulation beneath a skin substitute and allow for exudate removal,
wound dressings need to be porous. Biobrane was designed and is manufactured with
holes of approximately 1.5 mm diameter punctured through the silicone-nylon membrane
at approximately 0.5-inch centers. While this allows for some drainage, complications of
fluidaccumulationbeneaththedressing,leadingtosuppurationrequiring“windowing”and
antimicrobial intervention, have been reported.16 The patent-pending designs of AWBAT
enable the placement of precision pores in the silicone membrane without damaging or
disrupting the continuous 3-dimensional nylon structure (Fig 1). It is believed that a con-
tinuous nylon structure over the entire wound surface will better enable tissue ingrowth
and uniform healing with minimal scarring. The pores in AWBAT are spaced and sized
in a fashion to increase the porosity 500% to 1000% over Biobrane (Table 1), with the
intent to further minimize fluid accumulation beneath the skin substitute and the associated
complications.
By contrast, Integra’s silicone membrane (RTV) was not manufactured with pores;
as a result, fluid could accumulate beneath the membrane, which can lead to infection and
complications.Themanufacturer17 hassubsequentlyrecommendedmeshingthemembrane
to resolve this issue. Heimbach18 stated that his preference is to mesh Integra in order to
minimize fluid accumulation.
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Figure 1. Biobrane and AWBAT comparative structure and design: an illustration of the dif-
ference in the structure of Biobrane, AWBAT-S and AWBAT-M with respect to pore density,
poreconfiguration,andnylonstructureintegrity.Theleftscanningelectronmicroscope(SEM)
imagedepictsaholeofBiobraneandthedestructionofthe3-dimensionalnylonstructure.The
center image depicts a pore of AWBAT-S, which, designed as a superficial burn cover, is 500%
the porosity of Biobrane. The right image depicts a pore of AWBAT-M, which, designed as a
meshed autograft cover, is 1000% the porosity of Biobrane. Both AWBAT photographs show
the 3-dimensional structure of the nylon remaining intact and undamaged.
Infection control
The best defense against infection is a wound covering that sufficiently acts as a bacterial
barrier,whichthethicknessofthesiliconemembraneinBiobraneandAWBATprovides,and
the proper preparation of the wound. Improperly prepared and/or contaminated wounds are
not amenable to skin substitutes such as fresh or frozen human cadaver allograft, porcine
xenograft, Integra, Biobrane, and AWBAT.16 It is believed that when dressings such as
these are applied to clean, surgically debrided, or excised hemostatic wounds, antimicrobial
impregnation is not usually necessary.
Some clinicians have recently looked to antimicrobial activity as a safeguard against
infection, and many recently developed dressings contain silver ion as an antimicrobial
agent. While Biobrane, at approximately 1.2% porosity, was not designed specifically to
addressthepotentialdesireforantimicrobialpermeability,AWBATismoreaccommodating.
AWBAT-S,designedwith6%porosity,is500%morepermeabletowater-solubleantimicro-
bials such as mafenide acetate (Sulfamylon). AWBAT-D and AWBAT-M, with 12% porosity,
are 1000% more permeable. Diffusion of antimicrobials is directly related to the concentra-
tiongradientoftheantimicrobialacrosstheskinsubstituteandtheskinsubstitute’sporosity.
Theabilitytotreatendogenousmicrobeswithoutremovaloftheskinsubstitutebydiffusing
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antimicrobials through the skin substitute is highly desirable. It is believed that use of a
water-soluble antimicrobial over AWBAT in “borderline” contaminated wounds could con-
trol the proliferation of endogenous bacteria without necessitating removal of the dressing.
Physical adaptability
Stretchability, flexibility, conformability, and stability of a skin substitute are important to
the clinician,9 particularly when the wound is irregularly contoured. The stretchability and
flexibility of the dressing are critically important during rehabilitation when movement is
desired. The nylon component and the thinness of the silicone membrane in Biobrane and
AWBAT allows for these properties. Many wound dressings lacking these qualities become
stiff, inflexible, or “cast-like.” Other dressings can shrink or become degraded by wound
proteases.
Safety
Dressings should be sterile, hypoallergenic and nontoxic. Some skin substitutes, such as
fresh and frozen allograft, cannot guarantee sterility. Cadaver allograft has the potential
to transmit acquired immunodeficiency syndrome and hepatitis. As both glutaraldehyde
and formaldehyde are useful as sterilizing agents and reduce the antigenicity of biological
tissues,19 porcine xenograft has been treated with glutaraldehyde to improve its shelf life
and sterility safety margins; however, in the cross-linking process, the physical properties
of the product, such as adherence, have been compromised. Biobrane has proven to be safe,
with the exception of rare allergic reactions.20
ProductionofAWBATiscontrolledtomaximizesafetyandsterility(Table2),including
collagen application methods that eliminate the cross-linking agents used with Biobrane—
cyanuric acid and dodecylamine.
Punctate scarring is another rare complication reported with Biobrane.21 While the
causeisunknown,thescarringisalignedwiththeholesofBiobranewherethe3-dimensional
nylonstructureisdisrupted.ThecontinuityofnylonatAWBAT’sporesisintendedtomitigate
this potential.
Pain management
Pain reduction and patient comfort are desirable in wound care. Occlusive dressings that
appropriately cover exposed nerve endings and provide moist wound healing environments
characteristically reduce pain. They contrast sharply with nonocclusive dressings such as
scarlet red, Xeroform, and fine mesh gauze in their ability to ease pain.4 Barret et al22
report that Biobrane shows the significant benefits of being less painful with fewer dressing
changes over conventional antimicrobial treatments for second-degree burns in children.
AWBAT, like Biobrane, is a semiocclusive temporary skin substitute and is expected to
reduce pain, provide patient comfort, and enable quicker rehabilitation and ambulation.
Transparency
AWBAT,likeBiobrane,istransparenttoallowthecliniciantoobservethehealingprocessat
thewoundsurface.Theabilitytodetectsuppurationandimplementimmediatecorrectiveac-
tionsuchasantimicrobialtherapyisadistinctadvantageoverproductslackingtransparency.
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Stability
Long shelf life at room temperature is highly desirable.4 Storage requirements for allograft,
TransCyte, and other skin substitutes at refrigerated or subzero temperatures translate into
additional expense and inconvenience. AWBAT, like Biobrane, is designed to be sterile and
stable at room temperature for 3 years in an unaltered package.
Cost-effectiveness
Theultimatecostofanyskinsubstituteincludesnotonlytheproductbutalsothelengthand
complexity of patient care, including the expenses of dressing changes, complications, and
hospital stay. AWBAT, like Biobrane, is designed to remain in place on superficial burns,
donor sites, and meshed autografts for the life of the wound. It is also designed to mitigate
the potential for infection. Biobrane has proven to be cost-effective on superficial burns
compared with silver sulfadiazine (Silvadene) wound management, and some insurance
companies consider Biobrane medically necessary for the management of burns.3,22,23
Ease of application and removal
The ability to easily secure a skin substitute with staples, sutures, or steri-strips and easily
removeitinwholepieceswhennecessaryisdesirable.AWBAT,likeBiobrane,hasastretch-
able, conformable silicone-nylon component that can be easily attached by the clinician.
Thesilicone-nylonmembranealsohassufficientstrengthtoenableremovalwithouttearing.
Table 1. Similarities and differences of the Biobrane and AWBAT designs
Attributes Biobrane AWBAT-S AWBAT-D AWBAT-M
Intended use Superficial burns, donor
sites, excised wounds
(Biobrane); meshed
autografts (Biobrane-L)
Superficial burns Donor sites Meshed
autografts
Design
objective
15/3 (Biobrane) or 12/1
(Biobrane-L) denier
nylon—adherence
strong (Biobrane) or
light (Biobrane-L),
98.8% occlusive, single
porosity (1.2%)
15/2 denier
nylon—strong
adherence, 94%
occlusive,
porosity 6%
15/2 denier
nylon—strong
adherence, 88%
occlusive,
porosity 12%
12/1 denier
nylon—weak
acute and
secondary
adherence, 89%
occlusive,
porosity 11%
Silicone
component
Medical grade silicone Medical grade
silicone
Medical grade
silicone
Medical grade
silicone
Collagen
peptide
component
Porcine type 1 collagen
peptide (covalently
bound)
Porcine type 1
collagen
peptide
(mobile)
Porcine type 1
collagen
peptide
(mobile)
Porcine type 1
collagen
peptide
(mobile)
Cross-linking
agents used
Dodecylamine, cyanuric
chloride4
None used None used None used
Sterilizing
method
Autoclave 25 kGy E-beam
irradiation
25 kGy E-beam
irradiation
25 kGy E-beam
irradiation
Shelf life, y 3 3 3 3
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Table 2. AWBAT safety and sterility results from North American Science Associates, Inc
Test Scope Conclusion
ISO muscle implantation
study
2-wk evaluation for evidence of
irritation or toxicity
Macroscopic reaction was not
significant as compared with the
negative control implant;
microscopically classified as a
nonirritant
ISO systemic toxicity study 0.9% sodium chloride USP solution
and alcohol in saline 1:20 solution
extracts evaluated for systemic
toxicity
No mortality or evidence of
systemic toxicity from the extracts
ISO systemic toxicity study Sesame oil extracts evaluated for
systemic toxicity
No mortality or evidence of
systemic toxicity from the extracts
ISO intracutaneous study 0.9% sodium chloride solution and
sesame oil extracts evaluated for
intracutaneous reactivity
No erythema and no edema from the
SC extract and no to well-defined
erythema and edema from the SC
extracts
ASTM hemolysis Test article and extract in calcium-
and magnesium-free
phosphate-buffered saline
evaluated for in vitro red blood
cell hemolysis
The direct contact of the test article
was nonhemolytic, and the test
article extract was nonhemolytic
ISO maximization
sensitization study
0.9% sodium chloride solution and
sesame oil extracts evaluated for
the potential for delayed
dermal-contact sensitization
The SC and SO test article extracts
showed no evidence of causing
delayed dermal-contact
sensitization
Cytotoxicity study using the
ISO elution method
Single strength minimum essential
medium supplemented with 5%
serum and 2% antibiotics studied
for biocompatibility
Test article showed no evidence of
causing cell lysis or toxicity
E-beam radiation sterilization Establish radiation dose and validate
the effectiveness of E-beam
radiation for sterilization
Reaching minimum recommended
dose, the overall adjusted
bioburden was 31.7 CFU’s per
device, less than the maximum
bioburden of 1000 CFU allowed
by ISO 11137–2
ISO,InternationalOrganizationforStandardization;USP,UnitedStatesPharmacopeia;ASTM,AmericanSocietyforTesting
and Materials; SC, Sodium Chloride; SO, Seasame Oil: CFU, colony-forming unit.
CLINICAL EVALUATIONS
Numerous clinicians have expressed an interest in AWBAT and also in clinically evaluating
itsefficacy.ApilotstudywillevaluateAWBAT-SandAWBAT-Dinadonorsitemodel.Other
multicenter studies will examine AWBAT-S against Biobrane on clean, acute superficial
burns and AWBAT-D against Xeroform, Glucan II, and MepilexAg on donor sites.
WOUND HEALING ENHANCEMENT
In addition to the properties listed above, the optimal temporary skin substitute would
also enhance the body’s ability to heal itself. TransCyte, known for its ability to accelerate
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healing,24 used Biobrane as the scaffold on which newborn human fibroblast cells were
cultured. As the fibroblasts proliferated within Biobrane’s nylon mesh during the manufac-
turing process, they secreted human dermal collagen, matrix proteins, and growth factors.
The product was then frozen and required storage at −70˚F. While no cellular metabolic
activityremainedafterthefreezingprocess,thetissuematrixandboundgrowthfactorswere
left intact. Although seemingly successful, it is believed that TransCyte was discontinued
because it proved too expensive to manufacture and maintain.
As the search for an ideal temporary skin substitute is continually ongoing, the next
generation of AWBAT is currently under development. AWBAT-Plus, with patent-pending
design, is being created with the intent not only to capitalize on maximizing the ideal
properties discussed herein but also to cost-effectively enhance wound healing. AWBAT-
Plus is similar to AWBAT, utilizing the same precision porous silicone-nylon membrane,
exceptitcontains6xenogeniccomponents(Fig2).Inadditiontoasubstantialincreaseinthe
volume of porcine type I collagen peptides, it includes chondroitin-4-sulfate, chondroitin-
6-sulfate, vitamin E, vitamin C, and Immuno-10 (a highly purified fraction of Aloe).
Figure 2. AWBAT-Plus.
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CONCLUSION
While the search for the optimal skin substitute will continue, it is believed that AWBAT,
by design, beneficially expands upon the attributes of existing temporary skin substitutes to
betterfulfilltheidealpropertiesofabioengineeredalternativetissue.Theincreasedporosity
and continuity of the 3-dimensional silicone-nylon membrane is expected to improve acute
adherence and to reduce the potential for infection associated with fluid accumulation.
The elimination of cross-linking agents in the collagen application is expected to im-
prove the interaction with fibrin and to eliminate the potential for allergic reaction to those
agents. The retained benefits of pain management, physical adaptability, transparency, sta-
bility, cost-effectiveness, and ease of application and removal further define its advantages.
AWBAT-Plus, with the additional biological components, is projected to further improve
upon AWBAT’s benefits by enhancing wound healing.
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